Literature DB >> 23680332

Human T47D-ERβ breast cancer cells with tetracycline-dependent ERβ expression reflect ERα/ERβ ratios in rat and human breast tissue.

N M Evers1, T M C van de Klundert, Y M van Aesch, S Wang, W K de Roos, A Romano, L H J de Haan, A J Murk, A G H Ederveen, I M C M Rietjens, J P Groten.   

Abstract

T47D-ERβ breast cancer cells with tetracycline-dependent ERβ expression and constant ERα expression can be used to investigate effects of varying ERα/ERβ ratios on estrogen-induced cellular responses. This study defines conditions at which ERα/ERβ ratios in T47D-ERβ cells best mimic ERα/ERβ ratios in breast and other estrogen-sensitive tissues in vivo in rat as well as in human. Protein and mRNA levels of ERα and ERβ were analyzed in T47D-ERβ cells exposed to a range of tetracycline concentrations and compared to ERα and ERβ levels found in breast, prostate, and uterus from rat and human origin. The ERα/ERβ ratio in T47D-ERβ cells exposed to >150ng/ml tetracycline is comparable to the ratio found in rat mammary gland and in human breast tissue. The ERα/ERβ ratio of other estrogen-sensitive rat and human tissues can also be mimicked in T47D-ERβ cells. The ERα/ERβ ratio found in MCF-7 and native T47D breast cancer cell lines did not reflect ratios in analyzed rat and human tissues, which further supports the use of T47D-ERβ cells as model for estrogen-responsive tissues. Using 17β-estradiol and the T47D-ERβ cells under the conditions defined to mimic various tissues it could be demonstrated how these different tissues vary in their proliferative response.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  BPH; Breast tissue; DCC-FCS; DL; DMEM; DNA; Dulbecco’s modified Eagle’s medium; EC(50); EDTA; ER; ERα/ERβ ratio; Estrogen receptors; Estrogen-sensitive tissue; FCS; HE staining; HP1; IgG; In vitro–in vivo comparison; M-MLV; MCF-7 cells; MSD; Merck, Sharp & Dohme; Moloney Murine Leukemia Virus; PBS; PVDF; RT; SDS; T47D cells; T47D human ductal breast epithelial tumor cells with tetracycline-dependent ERβ expression; T47D-ERβ calibration standard, the T47D-ERβ cells without tetracycline; T47D-ERβ cells; T47D-ERβ cells with tetracycline dependent ERβ expression; T47D-ERβ-CS; benign prostatic hyperplasia; cDNA; complementary deoxyribonucleic acid; dNTP; deoxynucleotide triphosphate; deoxyribonucleic acid; detection limit; dextran-coated charcoal-treated fetal calf serum; estrogen receptor; ethylenediaminetetraacetic acid; fetal calf serum; half maximal effective concentration; hematoxylin and eosin staining; heterochromatin protein 1; human breast adenocarcinoma cells; human ductal breast epithelial tumor cells; immunoglobulin G; mRNA; messenger ribonucleic acid; phosphate buffered saline; polyvinylideenfluoride; qPCR; quantitative polymerase chain reaction; reverse transcriptase; sodium dodecyl sulfate

Mesh:

Substances:

Year:  2013        PMID: 23680332     DOI: 10.1016/j.tiv.2013.04.014

Source DB:  PubMed          Journal:  Toxicol In Vitro        ISSN: 0887-2333            Impact factor:   3.500


  3 in total

1.  In vitro-in silico-based analysis of the dose-dependent in vivo oestrogenicity of the soy phytoestrogen genistein in humans.

Authors:  Rungnapa Boonpawa; Albertus Spenkelink; Ans Punt; Ivonne M C M Rietjens
Journal:  Br J Pharmacol       Date:  2017-07-11       Impact factor: 8.739

2.  Soy supplementation: Impact on gene expression in different tissues of ovariectomized rats and evaluation of the rat model to predict (post)menopausal health effect.

Authors:  Mohammed A Islam; Guido J E J Hooiveld; Johannes H J van den Berg; Vera van der Velpen; Albertinka J Murk; Ivonne M C M Rietjens; F X Rolaf van Leeuwen
Journal:  Toxicol Rep       Date:  2018-10-24

3.  Development of a Generic Physiologically Based Kinetic Model to Predict In Vivo Uterotrophic Responses Induced by Estrogenic Chemicals in Rats Based on In Vitro Bioassays.

Authors:  Mengying Zhang; Bennard van Ravenzwaay; Ivonne M C M Rietjens
Journal:  Toxicol Sci       Date:  2020-01-01       Impact factor: 4.109

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.